Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-shNAMPT
- Development stage
- Preclinical
- Lead developer
- Chongqing Medical University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intravenous
01
Overview
Ad-shNAMPT is an adenovirus-mediated short hairpin RNA (shRNA) designed to knock down the expression of nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin. Developed as a research tool, Ad-shNAMPT has been investigated in preclinical models of atherosclerosis and insulin resistance. By inhibiting hepatic NAMPT expression, the agent promotes reverse cholesterol transport and cholesterol efflux via the PPARα-LXRα-ABCA1/G1 pathway, leading to antiatherogenic effects in vivo.
- Other names
- adenovirus-mediated short hairpin RNA targeting nicotinamide phosphoribosyltransferaseadenovirus-mediated short hairpin RNA targeting visfatin
02
Targets
NAMPT
Beyond the preview
Go deeper on Ad-shNAMPT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-shNAMPT.